- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04790370
Trombólise facilitada por ultrassom, dirigida por cateter, em embolia pulmonar de risco intermediário alto (HI-PEITHO)
Um estudo randomizado de trombólise guiada por cateter e facilitada por ultrassom versus anticoagulação para embolia pulmonar aguda de alto risco intermediário: o estudo de trombólise de embolia pulmonar de alto risco
There are many available treatments for pulmonary embolism (PE), but the best treatment for this condition is not known. The HI-PEITHO study will compare two treatment options that are both available on the market for the treatment of PE.
Patients will be randomized 1:1 to receive either blood thinners (anticoagulation) or blood thinners (anticoagulation) in combination with a device called the EkoSonicTM Endovascular device to dissolve blood clots. Patients will be followed for 12 months after randomization and have assessments while in the hospital as well as at 7 days, 30 days, 6 months and 12 months after randomization. The study will try to find out if one of these treatments is better than the other at reducing the risk of death and other serious problems.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This study will assess whether ultrasound-facilitated, catheter-directed thrombolysis and standard anticoagulation are associated with a significant reduction in the composite outcome of pulmonary embolism (PE)-related mortality, cardiorespiratory decompensation or collapse, or nonfatal symptomatic and objectively confirmed recurrence of PE compared to anticoagulation alone within seven days of randomization
The HI-PEITHO study has been designed to address the important gaps in clinical evidence by comparing the clinical benefit of the ultrasound-facilitated local delivery of a low dose thrombolytic agent and anticoagulation with those of anticoagulation alone in patients with intermediate-high risk PE at a higher estimated risk of early decompensation based on clinical parameters at presentation.
This study has a focus on improving the safety of thrombolysis and advancing the concept of intermediate-high risk and the PE severity criteria, to better identify patients who may clinically benefit from thrombolysis.
The results of this study will contribute further evidence to the existing data on the treatment and outcomes of acute, intermediate-high risk PE and provide controlled data related to catheter-based interventions.
Data will be entered by the site into an electronic database. The database will include data checks to compare data entered into the database against predefined rules for ranges and consistency with other data fields in the database.
Site monitoring will take place with source data verification to assess the accuracy and completeness of registry data by comparing the data to medical records and study assessments.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 4
Contactos e Locais
Locais de estudo
-
-
-
Aachen, Alemanha
- Uniklinik Aachen
-
Bielefeld, Alemanha
- Klinikum Bielefeld
-
Bonn, Alemanha
- GFO Kliniken Bonn
-
Chemnitz, Alemanha
- Klinikum Chemnitz
-
Freiburg im Breisgau, Alemanha
- Universitaetsklinikum Freiburg
-
Immenstädt, Alemanha
- Klinik Immenstadt
-
Lübeck, Alemanha
- Universitaetsklinikum Schleswig-Holstein
-
Mainz, Alemanha
- Johannes Gutenberg Universitaet Mainz
-
Munich, Alemanha
- Klinikum Rechts der Isar
-
Tübingen, Alemanha
- Universitaetsklinikum Tuebingen
-
Würzburg, Alemanha
- Universitaetsklinikum Wuerzburg
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35294
- University of Alabama at Birmingham
-
-
California
-
Los Angeles, California, Estados Unidos, 90048
- Cedars - Sinai Medical Center
-
-
Delaware
-
Newark, Delaware, Estados Unidos, 19718
- Christiana Hospital
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Emory University Hospital
-
Atlanta, Georgia, Estados Unidos, 30309
- Piedmont Hospital
-
Augusta, Georgia, Estados Unidos, 30904
- Augusta University
-
-
Indiana
-
Merrillville, Indiana, Estados Unidos, 46410
- Methodist Hospitals
-
-
Kentucky
-
Lousville, Kentucky, Estados Unidos, 40207
- Baptist Health East Louisville
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21201
- University of Maryland School of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- University of Michigan Hospitals
-
Detroit, Michigan, Estados Unidos, 48202
- Henry Ford Hospital
-
-
Mississippi
-
Tupelo, Mississippi, Estados Unidos, 38801
- North Mississippi Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68114
- Nebraska Methodist Hospital
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03756
- Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Newark, New Jersey, Estados Unidos, 07112
- Newark Beth Israel Medical Center
-
-
New York
-
New York, New York, Estados Unidos, 10032
- Columbia University Medical Center
-
New York, New York, Estados Unidos, 10029
- Mount Sinai Medical Center
-
New York, New York, Estados Unidos, 10075
- Lenox Hill Hospital
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- University Hospitals of Cleveland
-
Kettering, Ohio, Estados Unidos, 45429
- Kettering Health
-
-
Tennessee
-
Kingsport, Tennessee, Estados Unidos, 37660
- Wellmont Holston Valley Medical Center
-
Nashville, Tennessee, Estados Unidos, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Austin, Texas, Estados Unidos, 78705
- Seton Medical Center
-
Houston, Texas, Estados Unidos, 77479
- Houston Methodist Sugarland Hospital
-
Plano, Texas, Estados Unidos, 75093
- The Heart Hospital Baylor Plano
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22908
- University of Virginia Medical Center
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- University of Wisconsin Hospitals
-
-
-
-
-
Besançon, França
- CHU de Besancon
-
Nîmes, França
- CHU (Nimes Cedex)
-
Paris, França
- Hôpital Européen Georges Pompidou (HEGP)
-
-
-
-
-
Leiden, Holanda
- Leiden University Medical Center
-
Nieuwegein, Holanda
- St. Antonius Ziekenhuis
-
Utrecht, Holanda
- Universitair Medisch Centrum
-
-
-
-
-
Dublin, Irlanda
- Mater Misericordiae University Hospital
-
Galway, Irlanda
- University Hospital Galway
-
-
-
-
-
Krakow, Polônia
- John Paul II Hospital
-
Poznan, Polônia
- Uniwersytecki Szpital Kliniczny w Poznaniu
-
Warsaw, Polônia
- Medical University of Warsaw
-
-
-
-
-
Cardiff, Reino Unido
- University Hospital of Wales
-
London, Reino Unido
- The Royal Free Hospital
-
Middlesex, Reino Unido
- Northwick Park Hospital
-
-
-
-
-
Basel, Suíça
- University Hospital Basel
-
Lausanne, Suíça
- Centre Hospitalier Universitaire Vaudois
-
Zurich, Suíça
- University Hospital Zurich
-
-
-
-
-
Innsbruck, Áustria
- A.o. LKH Univ.-Kliniken Innsbruck
-
Sankt Pölten, Áustria
- Universitätsklinikum St. Pölten
-
Vienna, Áustria
- Allgemeines Krankenhaus AKH
-
Vienna, Áustria
- Austria Klinik Ottakring Vienna
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Age 18-80 years, inclusive
-
Objectively confirmed acute PE, based on computed tomography pulmonary angiography (CTPA) showing a filling defect in at least one main or proximal lobar pulmonary artery
-
Elevated risk of early death/hemodynamic collapse, indicated by at least two of the following new-onset clinical criteria:
- ECG-documented tachycardia with heart rate ≥100 beats per minute, not due to hypovolemia, arrhythmia, or sepsis;
- SBP ≤ 110 mm Hg for at least 15 minutes;
- respiratory rate > 20 x min^-1 or oxygen saturation on pulse oximetry (SpO2) < 90% (or partial arterial oxygen pressure < 60 mmHg) at rest while breathing room air;
-
Right-to-left ventricular (RV/LV) diameter ratio ≥ 1.0 on CTPA
-
Serum troponin I or T levels above the upper limit of normal
-
Signed informed consent
Exclusion Criteria:
-
Hemodynamic instability*, i.e. at least one of the following present:
- cardiac arrest or need for cardiopulmonary resuscitation;
- need for ECMO, or ECMO initiated before randomization
- PE-related shock, defined as: (i) SBP < 90 mmHg, or vasopressors required to achieve SBP ≥ 90 mmHg, despite an adequate volume status; and (ii) end-organ hypoperfusion (altered mental status; oliguria/anuria; increased serum lactate);
- isolated persistent hypotension (SBP < 90 mmHg, or a systolic pressure drop by at least 40 mmHg for at least 15 minutes), not caused by new-onset arrhythmia, hypovolemia, or sepsis * Patients who presented with temporary need for fluid resuscitation and/or low-dose catecholamines may be included, provided that they could be stabilized within 2 hours of admission and maintain SBP of ≥ 90 mmHg and adequate organ perfusion without catecholamine infusion.
-
Need for admission to an intensive care unit for a reason other than the index PE episode. NB: Patients who test positive for SARS-CoV-2 can be enrolled where the investigator believes that the pulmonary embolism is the dominant pathology in the patient's clinical presentation and qualifying cardiorespiratory parameters.
-
Temperature above 39 degrees C / 102.2 degrees F
-
Logistical reasons limiting the rapid availability of interventional procedures to treat acute PE (e.g., during the outbreak of an epidemic)
-
Index PE symptom duration > 14 days
-
Active bleeding
-
History of intracranial or intraocular bleeding at any time
-
Stroke or transient ischemic attack within the past 6 months, or previous stroke at any time if associated with permanent disability
-
Central nervous system neoplasm, or metastatic cancer
-
Major neurologic, ophthalmologic, abdominal, cardiac, thoracic, vascular or orthopedic surgery or trauma (including syncope-associated with head strike or skeletal fracture) within the past 3 weeks
-
Platelet count < 100 x 10^9 x L^-1
-
Patients who have received a once-daily therapeutic dose of LMWH or a therapeutic dose of fondaparinux within 24 hours prior to randomization
-
Patients who have received one of the direct oral anticoagulants apixaban or rivaroxaban within 12 hours prior to randomization
-
Patients who have received one of the direct oral anticoagulants dabigatran or edoxaban for the index PE episode, as these drugs are not approved for patients who have not received heparin for at least 5 days
-
Administration of a thrombolytic agent or a glycoprotein IIb/IIIa receptor antagonist during the current hospital stay and/or within 30 days, for any reason
-
Chronic treatment with antiplatelet agents other than low-dose acetylsalicylic acid or clopidogrel 75 mg once daily (but not both). Dual antiplatelet therapy is excluded.
-
Chronic treatment with a direct oral anticoagulant (apixaban, dabigatran, edoxaban or rivaroxaban)
-
Chronic treatment with a vitamin K antagonist, or known coagulopathy including severe hepatic dysfunction, with an International Normalized Ratio (INR) > 1.5
-
Pregnancy or lactation
-
Previous inclusion in the study
-
Known hypersensitivity to alteplase, LMWH or UFH, or to any of the excipients
-
Life expectancy less than 6 months
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Anticoagulation
Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH) |
Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)
Outros nomes:
|
|
Comparador Ativo: Anticoagulation and EkoSonicTM Endovascular System
Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH) and EkoSonicTM Endovascular System [ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg] |
Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)
Outros nomes:
EkoSonicTM Endovascular System [ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg]
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants With PE-Related Mortality
Prazo: Within seven days of randomization
|
Death resulting from pulmonary embolism occurring within the assessment period. |
Within seven days of randomization
|
|
Number of Participants With Recurrent Pulmonary Embolism
Prazo: Within seven days of randomization
|
Symptomatic, objectively confirmed, nonfatal recurrent pulmonary embolism occurring during the assessment period. |
Within seven days of randomization
|
|
Number of Participants With Cardiorespiratory Decompensation or Collapse
Prazo: Within seven days of randomization
|
Cardiorespiratory collapse or decompensation is defined as at least one of the following criteria:
|
Within seven days of randomization
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change From Baseline in Right Ventricular-to-Left Ventricular (RV-to-LV) Diameter Ratio
Prazo: Baseline and 48 hours after the index procedure
|
The RV-to-LV diameter ratio was assessed by echocardiography at baseline and 48 hours after the index procedure. The ratio was calculated by dividing the right ventricular diameter by the left ventricular diameter. Change from baseline was defined as the difference between the 48-hour and baseline measurements. Higher RV-to-LV ratios indicate greater right ventricular dilation, whereas lower ratios indicate less right ventricular dilation and improvement in right ventricular size relative to the left ventricle. |
Baseline and 48 hours after the index procedure
|
|
Number of Participants With Cardiorespiratory Decompensation
Prazo: Within seven days of randomization
|
The number of participants who experienced cardiorespiratory decompensation within 7 days of randomization. Cardiorespiratory decompensation was defined as the occurrence of any of the following: cardiac arrest or receipt of cardiopulmonary resuscitation (CPR), signs of shock, placement on extracorporeal membrane oxygenation (ECMO), intubation or initiation of non-invasive mechanical ventilation, or a National Early Warning Score (NEWS) of 9 or greater. Participants were counted once if they experienced one or more of these events during the 7-day assessment period. |
Within seven days of randomization
|
|
Number of Participants With GUSTO Major (Moderate or Severe) Bleeding
Prazo: Within seven days of randomization
|
Major bleeding will be adjudicated according to the GUSTO criteria:
|
Within seven days of randomization
|
|
Number of Participants With International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding
Prazo: Within 7 days, 30 days, and 6 months of randomization
|
Major bleeding will also be adjudicated according to the ISTH criteria:
|
Within 7 days, 30 days, and 6 months of randomization
|
|
Number of Participants With Ischemic or Hemorrhagic Stroke
Prazo: Within 7 days and 30 days following randomization
|
Occurrence of ischemic or hemorrhagic stroke during the assessment period. Participants were counted once for each assessment time point if an ischemic or hemorrhagic stroke occurred. |
Within 7 days and 30 days following randomization
|
|
Number of Participants With All-Cause Mortality
Prazo: Within 7 days, 30 days, 6 months, and 12 months of randomization
|
Death from any cause. |
Within 7 days, 30 days, 6 months, and 12 months of randomization
|
|
Number of Participants With at Least One Serious Adverse Event
Prazo: Within 30 days of randomization
|
Number of participants who experienced at least one serious adverse event. |
Within 30 days of randomization
|
|
Number of Participants With All-Cause Mortality, Cardiorespiratory Collapse or Decompensation, or Recurrent Pulmonary Embolism
Prazo: Within 30 days of randomization
|
Death due to any cause, Cardiorespiratory collapse or decompensation should fulfill at least one of the following criteria:
|
Within 30 days of randomization
|
|
Number of Participants With Symptomatic Recurrent Pulmonary Embolism
Prazo: Within 30 days and 6 months of randomization
|
Number of participants who experienced symptomatic recurrent pulmonary embolism. |
Within 30 days and 6 months of randomization
|
|
Change From Baseline in RV Dysfunction on Echocardiography
Prazo: 6 months
|
Right ventricle to left ventricle end diastolic diameter ratio (RV/LV). |
6 months
|
|
Duration of Hospitalization for the Index Pulmonary Embolism Event
Prazo: Within 30 days of randomization
|
Length of hospital stay was calculated as the number of days between hospital admission and hospital discharge. |
Within 30 days of randomization
|
|
Duration of Stay in the Intensive Care Unit (ICU), Intermediate Care Unit, or Coronary Care Unit for the Index Pulmonary Embolism Event
Prazo: Within 30 days of randomization
|
Length of stay was calculated as the time between admission to and discharge from the intensive care unit (ICU), intermediate care unit, or coronary care unit during hospitalization. |
Within 30 days of randomization
|
|
Functional Status as Measured by World Health Organization (WHO) Functional Class
Prazo: Up to 7 days, 30 days, 6 and 12 months of randomization
|
WHO Functional Class categorizes symptom severity and physical activity limitation. Class I indicates no limitation of physical activity; Class II indicates slight limitation of physical activity; Class III indicates marked limitation of physical activity; and Class IV indicates inability to perform physical activity without symptoms, with symptoms that may be present at rest. Lower classes (I-II) represent better functional status, whereas higher classes (III-IV) represent worse functional status. Participants were classified according to WHO Functional Class at each assessment time point. |
Up to 7 days, 30 days, 6 and 12 months of randomization
|
|
Functional Status as Measured by 6-Minute Walk Test (6MWT)
Prazo: 30 days, 6 months, and 12 months of randomization
|
The 6MWT measures the distance a patient can walk on a flat surface in a period of 6 minutes. A 100-meter distance is measured in a hallway, and the patient is asked to walk quickly as many laps as they can over the course of the timed test. Greater distances indicate better functional exercise capacity, whereas shorter distances indicate greater functional limitation. The total distance is measured. The patient's baseline vitals and symptoms are compared to their condition at the completion of the test. |
30 days, 6 months, and 12 months of randomization
|
|
Functional Status as Measured by Post-Venous Thromboembolism Functional Status (PVFS) Scale
Prazo: 30 days, 6 months, and 12 months of randomization
|
The Post-Venous Thromboembolism Functional Status (PVFS) Scale assesses functional limitations following a venous thromboembolic event. Participants are classified according to the following grades: Grade 0 = no functional limitations or symptoms; Grade 1 = symptoms present but no limitations in usual activities; Grade 2 = slight functional limitations requiring occasional modification of activities; Grade 3 = moderate functional limitations requiring regular modification of activities; Grade 4 = severe functional limitations with inability to perform usual activities without assistance; Grade 5 = death. Lower grades (0-1) indicate better functional status and less disability, while higher grades (3-4) indicate worse functional status and greater disability. Participants were assessed at each study time point and classified according to the PVFS grade that best described their functional status. |
30 days, 6 months, and 12 months of randomization
|
|
Quality of Life Using PEmb-QOL
Prazo: 6 and 12 months
|
PEmb-QOL is a questionnaire that assesses post-pulmonary embolism quality of life in the context of pulmonary-specific symptoms. The PEmb-QOL questionnaire contains six dimensions based on the contents of the items: frequency of complaints, limitations in activities of daily living, work-related problems, social limitations, intensity of complaints and emotional complaints. Higher scores indicate worse outcome. |
6 and 12 months
|
|
Quality of Life Using SF-36
Prazo: 6 and 12 months
|
The SF-36 questionnaire is a generic quality of life measure containing eight health domains (physical functioning, physical role, pain, general health, vitality, social function, emotional role functioning, and mental health). The scoring is on a 0-100 scale, with a higher score indicating better health. Scores are combined into two overall summary scores: physical health summary score and mental health summary score. |
6 and 12 months
|
|
Quality of Life Using EQ-5D Scale
Prazo: 6 and 12 months
|
The EQ-5D is a patient reported outcome that provides a simple descriptive profile and single index value for health status. The questionnaire consists of 5 questions pertaining to specific health dimensions, including mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and overall health status rating scale. |
6 and 12 months
|
|
Diagnosis of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Prazo: Within 12 months
|
CTEPH will be diagnosed by the investigational site according to presence of all of the following criteria:
|
Within 12 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Stavros Konstantinides, MD, University Medical Center Mainz, Mainz, Germany
- Investigador principal: Kenneth Rosenfield, MD, Massachusetts General Hospital, Boston, Massachusetts, USA
Publicações e links úteis
Publicações Gerais
- Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83.
- Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449. No abstract available.
- Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, Bluhmki E, Bouvaist H, Brenner B, Couturaud F, Dellas C, Empen K, Franca A, Galie N, Geibel A, Goldhaber SZ, Jimenez D, Kozak M, Kupatt C, Kucher N, Lang IM, Lankeit M, Meneveau N, Pacouret G, Palazzini M, Petris A, Pruszczyk P, Rugolotto M, Salvi A, Schellong S, Sebbane M, Sobkowicz B, Stefanovic BS, Thiele H, Torbicki A, Verschuren F, Konstantinides SV; PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014 Apr 10;370(15):1402-11. doi: 10.1056/NEJMoa1302097.
- Kucher N, Boekstegers P, Muller OJ, Kupatt C, Beyer-Westendorf J, Heitzer T, Tebbe U, Horstkotte J, Muller R, Blessing E, Greif M, Lange P, Hoffmann RT, Werth S, Barmeyer A, Hartel D, Grunwald H, Empen K, Baumgartner I. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation. 2014 Jan 28;129(4):479-86. doi: 10.1161/CIRCULATIONAHA.113.005544. Epub 2013 Nov 13.
- Kuo WT, Banerjee A, Kim PS, DeMarco FJ Jr, Levy JR, Facchini FR, Unver K, Bertini MJ, Sista AK, Hall MJ, Rosenberg JK, De Gregorio MA. Pulmonary Embolism Response to Fragmentation, Embolectomy, and Catheter Thrombolysis (PERFECT): Initial Results From a Prospective Multicenter Registry. Chest. 2015 Sep;148(3):667-673. doi: 10.1378/chest.15-0119.
- Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005 Apr;3(4):692-4. doi: 10.1111/j.1538-7836.2005.01204.x.
- Piazza G, Hohlfelder B, Jaff MR, Ouriel K, Engelhardt TC, Sterling KM, Jones NJ, Gurley JC, Bhatheja R, Kennedy RJ, Goswami N, Natarajan K, Rundback J, Sadiq IR, Liu SK, Bhalla N, Raja ML, Weinstock BS, Cynamon J, Elmasri FF, Garcia MJ, Kumar M, Ayerdi J, Soukas P, Kuo W, Liu PY, Goldhaber SZ; SEATTLE II Investigators. A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study. JACC Cardiovasc Interv. 2015 Aug 24;8(10):1382-1392. doi: 10.1016/j.jcin.2015.04.020.
- Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8. doi: 10.1016/j.echo.2010.05.010. No abstract available.
- Klok FA, Cohn DM, Middeldorp S, Scharloo M, Buller HR, van Kralingen KW, Kaptein AA, Huisman MV. Quality of life after pulmonary embolism: validation of the PEmb-QoL Questionnaire. J Thromb Haemost. 2010 Mar;8(3):523-32. doi: 10.1111/j.1538-7836.2009.03726.x. Epub 2009 Dec 15.
- Smith GB, Prytherch DR, Meredith P, Schmidt PE, Featherstone PI. The ability of the National Early Warning Score (NEWS) to discriminate patients at risk of early cardiac arrest, unanticipated intensive care unit admission, and death. Resuscitation. 2013 Apr;84(4):465-70. doi: 10.1016/j.resuscitation.2012.12.016. Epub 2013 Jan 4.
- Becattini C, Agnelli G, Lankeit M, Masotti L, Pruszczyk P, Casazza F, Vanni S, Nitti C, Kamphuisen P, Vedovati MC, De Natale MG, Konstantinides S. Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. Eur Respir J. 2016 Sep;48(3):780-6. doi: 10.1183/13993003.00024-2016. Epub 2016 May 12.
- Steering Committee. Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Am Heart J. 2012 Jan;163(1):33-38.e1. doi: 10.1016/j.ahj.2011.10.003.
- Tapson VF, Sterling K, Jones N, Elder M, Tripathy U, Brower J, Maholic RL, Ross CB, Natarajan K, Fong P, Greenspon L, Tamaddon H, Piracha AR, Engelhardt T, Katopodis J, Marques V, Sharp ASP, Piazza G, Goldhaber SZ. A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism: The OPTALYSE PE Trial. JACC Cardiovasc Interv. 2018 Jul 23;11(14):1401-1410. doi: 10.1016/j.jcin.2018.04.008.
- Marti C, John G, Konstantinides S, Combescure C, Sanchez O, Lankeit M, Meyer G, Perrier A. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2015 Mar 7;36(10):605-14. doi: 10.1093/eurheartj/ehu218. Epub 2014 Jun 10.
- Barco S, Vicaut E, Klok FA, Lankeit M, Meyer G, Konstantinides SV; PEITHO Investigators. Improved identification of thrombolysis candidates amongst intermediate-risk pulmonary embolism patients: implications for future trials. Eur Respir J. 2018 Jan 18;51(1):1701775. doi: 10.1183/13993003.01775-2017. Print 2018 Jan. No abstract available.
- Bajaj NS, Kalra R, Arora P, Ather S, Guichard JL, Lancaster WJ, Patel N, Raman F, Arora G, Al Solaiman F, Clark DT 3rd, Dell'Italia LJ, Leesar MA, Davies JE, McGiffin DC, Ahmed MI. Catheter-directed treatment for acute pulmonary embolism: Systematic review and single-arm meta-analyses. Int J Cardiol. 2016 Dec 15;225:128-139. doi: 10.1016/j.ijcard.2016.09.036. Epub 2016 Sep 20.
- GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993 Sep 2;329(10):673-82. doi: 10.1056/NEJM199309023291001.
- Liu VX, Lu Y, Carey KA, Gilbert ER, Afshar M, Akel M, Shah NS, Dolan J, Winslow C, Kipnis P, Edelson DP, Escobar GJ, Churpek MM. Comparison of Early Warning Scoring Systems for Hospitalized Patients With and Without Infection at Risk for In-Hospital Mortality and Transfer to the Intensive Care Unit. JAMA Netw Open. 2020 May 1;3(5):e205191. doi: 10.1001/jamanetworkopen.2020.5191.
- Quiroz R, Kucher N, Schoepf UJ, Kipfmueller F, Solomon SD, Costello P, Goldhaber SZ. Right ventricular enlargement on chest computed tomography: prognostic role in acute pulmonary embolism. Circulation. 2004 May 25;109(20):2401-4. doi: 10.1161/01.CIR.0000129302.90476.BC. Epub 2004 May 17.
- Stein PD, Matta F, Yaekoub AY, Goodman LR, Sostman HD, Weg JG, Hales CA, Hull RD, Leeper KV Jr, Beemath A, Saeed IM, Woodard PK. Reconstructed 4-chamber views compared with axial imaging for assessment of right ventricular enlargement on CT pulmonary angiograms. J Thromb Thrombolysis. 2009 Oct;28(3):342-7. doi: 10.1007/s11239-009-0331-5. Epub 2009 Mar 27.
- Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016 Jan;41(1):206-32. doi: 10.1007/s11239-015-1310-7.
- Cech DJ, Martin ST. Evaluation of function, activity, and participation. Functional Movement Development Across the Life Span (Third Edition), 2012.
- Saris-Baglama RN, Dewey CJ, Chisholm GB, et al. QualityMetric health outcomes™ scoring software 4.0. Lincoln, RI: QualityMetric Incorporated, 2010, p. 138.
- Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jimenez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, Ni Ainle F, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan 21;41(4):543-603. doi: 10.1093/eurheartj/ehz405. No abstract available.
- Klok FA, Piazza G, Sharp ASP, Ni Ainle F, Jaff MR, Chauhan N, Patel B, Barco S, Goldhaber SZ, Kucher N, Lang IM, Schmidtmann I, Sterling KM, Becker D, Martin N, Rosenfield K, Konstantinides SV. Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. Am Heart J. 2022 Sep;251:43-53. doi: 10.1016/j.ahj.2022.05.011. Epub 2022 May 16.
- Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016 Feb;149(2):315-352. doi: 10.1016/j.chest.2015.11.026. Epub 2016 Jan 7.
- Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, Jenkins JS, Kline JA, Michaels AD, Thistlethwaite P, Vedantham S, White RJ, Zierler BK; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011 Apr 26;123(16):1788-830. doi: 10.1161/CIR.0b013e318214914f. Epub 2011 Mar 21.
- ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. doi: 10.1164/ajrccm.166.1.at1102. No abstract available.
- Rosenfield K, Klok FA, Piazza G, Sharp ASP, Ni Ainle F, Jaff MR, Barco S, Goldhaber SZ, Kucher N, Lang IM, Schmidtmann I, Sterling KM, Araszkiewicz A, Arora V, Cires-Drouet R, Coghlan J, Hobohm L, Ito WD, Jacobson K, Kaiser C, Kopec G, Marx K, McElwee S, Meneveau N, Monteleone P, Montero-Cabezas JM, Olivier CB, Park J, Roik M, Sakhuja R, Tego A, Theurl M, Visveswaran G, Vos JA, Young MN, Asch FM, Konstantinides SV; HI-PEITHO Investigators. Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism. N Engl J Med. 2026 May 28;394(20):1979-1990. doi: 10.1056/NEJMoa2516567. Epub 2026 Mar 28.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- S2479
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .